The guidance in this document is based on experience from UK centres with the greatest experience of looking after patients with COVID-19 disease and will be updated as more evidence becomes available.  The document provides helpful algorithms for management and treatment.

Caution - COVID-19 infection in people with or without previously recognised diabetes increases the risk of the EMERGENCY states of hyperglycaemia with ketones, Diabetic KetoAcidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS)

Combined liraglutide-insulin therapy is associated with metabolic improvement and insulin dose reduction in commonly prescribed insulin regimens

Piya Sen Gupta¹, Ken Y Thong², Christopher Walton³, Robert EJ Ryder¹, on behalf of ABCD liraglutide audit contributors

¹City Hospital, Birmingham, UK

²Rockingham General Hospital, Perth, Australia

³Hull Royal Infirmary, Hull, UK

NICE guidelines versus clinical practice – GLP-1 receptor agonists in type 2 diabetes: the ABCD nationwide audits

KY Thong¹, P Sen Gupta², ML Cull², KA Adamson³, DS Dove⁴, SV Rowles⁵, S Tarpey⁵, C Duncan⁶ , J Chalmers⁶, R Harper⁷, P McDonald⁷, U Brennan⁷, C Walton⁸, REJ Ryder² on behalf of the ABCD Nationwide exenatide^* and liraglutide^† audit contributors

The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits

KY Thong¹, P Sen Gupta^1,2, REJ Ryder¹

¹Department of Diabetes, City Hospital, Birmingham, UK

²Diabetes Research Group, King’s College, London, UK

Does Liraglutide Therapy Affect the Metabolic Response in Patients with An Elevated Alanine Aminotransferase and Type 2 Diabetes Mellitus?: The Association of British Clinical Diabetologists (ABCD) Nationwide Liraglutide Audit

Sen Gupta P¹, Thong KY¹, Armstrong M², Newsome PN², Winocour P³, Ryder REJ¹

¹City Hospital, Birmingham, UK

²University of Birmingham, Birmingham, UK

³Queen Elizabeth Hospital, Welwyn Garden City, UK

Liraglutide and acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

Ryder REJ¹, Thong KY², Blann A¹, Phillips S³, Barwell N⁴, Kelly C⁴, Semple C⁵, Struthers S⁵, Sen Gupta P¹, on behalf of the ABCD Nationwide Liraglutide Audit contributors

¹City Hospital, Birmingham, UK

²Rockingham General Hospital, Perth, Australia

³Gloucestershire Royal Hospital, UK

Combined insulin and liraglutide is associated with metabolic improvement and reduction in insulin dose in commonly prescribed insulin regimens: an ABCD Nationwide Liraglutide Audit analysis RESULTS Fig. 1. The pie chart shows the breakdown of patients by insulin regime at liraglutide initiation in terms of number of patients (%). Table 1. Baseline characteristics of patients categorised by their insulin regime at liraglutide initiation. P values: *<0.01, **<0.001, ***<0.0001 P

Does Liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and type 2 diabetes mellitus?: ABCD Nationwide Liraglutide Audit RESULTS Table 1. Baseline characteristics categorised by baseline ALT

P Sen Gupta^1,2, KY Thong¹, M Cull¹, P Winocour³, REJ Ryder¹, on behalf of the ABCD nationwide liraglutide audit

¹City Hospital, Birmingham

²King’s College, London

³Queen Elizabeth II Hospital, Hertfordshire

Liraglutide is effective across a range of overweight and obese body mass indices; findings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

Ryder REJ¹, Sen-Gupta P¹, Thong KY¹

¹City Hospital, Birmingham, UK